Thousands of Kenyans are set for a reprieve after the US authorities on Wednesday approved an injection vaccine for preventing HIV and AIDs disease. The US Food and Drug Administration approved Gilead Sciences' new drug, lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.
The approved drug, Lenacapavir, developed by Gilead Sciences, will be marketed under the brand name Yeztugo. It is a twice-yearly injection designed to prevent HIV infection in both adults and adolescents, offering an alternative to daily oral pills.
A photo of an HIV test specimen.
File Lenacapavir belongs to a new class of antiretrovirals known as capsid inhibitors.
